CN102145014B - Pharmaceutical composition for treating peptic ulcer, preparation method and use of pharmaceutical composition - Google Patents
Pharmaceutical composition for treating peptic ulcer, preparation method and use of pharmaceutical composition Download PDFInfo
- Publication number
- CN102145014B CN102145014B CN2011100611336A CN201110061133A CN102145014B CN 102145014 B CN102145014 B CN 102145014B CN 2011100611336 A CN2011100611336 A CN 2011100611336A CN 201110061133 A CN201110061133 A CN 201110061133A CN 102145014 B CN102145014 B CN 102145014B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- preparation
- vinegar
- ulcer
- endoconcha sepiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 208000008469 Peptic Ulcer Diseases 0.000 title claims abstract description 14
- 208000011906 peptic ulcer disease Diseases 0.000 title claims abstract description 12
- 235000021419 vinegar Nutrition 0.000 claims abstract description 35
- 239000000052 vinegar Substances 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 208000015864 chronic erosive gastritis Diseases 0.000 claims abstract description 14
- 238000009472 formulation Methods 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 31
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 14
- 201000005917 gastric ulcer Diseases 0.000 claims description 13
- 206010062532 Erosive duodenitis Diseases 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 241000180579 Arca Species 0.000 claims description 10
- 201000003639 autosomal recessive cerebellar ataxia Diseases 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 208000000718 duodenal ulcer Diseases 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 8
- 210000001198 duodenum Anatomy 0.000 abstract description 5
- 230000003628 erosive effect Effects 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 206010017886 Gastroduodenal ulcer Diseases 0.000 abstract 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 14
- 208000025865 Ulcer Diseases 0.000 description 13
- 238000001839 endoscopy Methods 0.000 description 13
- 231100000397 ulcer Toxicity 0.000 description 13
- 206010000087 Abdominal pain upper Diseases 0.000 description 10
- 230000035876 healing Effects 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010067171 Regurgitation Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000000589 cicatrix Anatomy 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 229940069428 antacid Drugs 0.000 description 4
- 239000003159 antacid agent Substances 0.000 description 4
- 230000001458 anti-acid effect Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 241001663378 Sepiella maindroni Species 0.000 description 2
- 241000238371 Sepiidae Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241000628923 Anadara sativa Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 241001339782 Scapharca broughtonii Species 0.000 description 1
- 241001441745 Sepia esculenta Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000224239 Tegillarca granosa Species 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating peptic ulcer, comprising formulation prepared by the following raw materials by weight: 4-6 parts of vinegar concha arcae and 1 part of cuttlebone. The invention further discloses a preparation method and use of the pharmaceutical composition. The pharmaceutical composition is free from side toxic effect and capable of efficiently treating stomach, gastroduodenal ulcer, erosive duodenum and chronic erosive gastritis; through clinical verification, the pharmaceutical composition can rapidly relieve clinic symptoms of ached upper stomach and the like; the curing time is short, and the curing rate is 100%. The invention provides new selection for clinical application for treating peptic ulcer, the erosive duodenum and the chronic erosive gastritis.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of peptic ulcer, and its production and use.Belong to drug world.
Background technology
Stomach duodenum ulcer refers to the circular or oval full-thickness defects of the limitation of Grastiodudenal mucosa, and muscularis mucosae is penetrated, and leaves inevitably fibrous scar after the healing, and the surface is covered by one deck epithelium, and muscularis mucosae can not be regenerated.Its cause of disease sum up be since many reasons to cause gastric acid, pepsin destroyed to self-digestion or the gastric mucosal barrier of gastric mucosa.Think that in recent years formation and the gastric Helicobacter pylori infection of ulcer also have important relationship.
Chronic erosive gastritis claims again the indigestion symptoms such as general rarely seen after meal glutted, the pantothenic acid of gastritis verrucosa or varioliform gastritis, belch, irregularities stomachache.A plurality of excipuliforms appear in the Stomach in Patients mucosa, expand folded shape or pimple sample protuberance, diameter 5～10mm, and the visible Mucosa Defect in top or umbilicus sample depression, there is erosion at the center, and many without blush around the protuberance, but normal with the similar erythema of size, section is common with gastric antrum.
Duodenal erosion is the shallow depression of mucous layer, and its degree of depth is not passed muscularis mucosae, the point-like that takes on a red color, and diameter is generally less than 0.5cm.Do not stay cicatrix after the healing.
The medicine of the above-mentioned disease of current treatment mostly is chemical drugs, and it is expensive, and side effect is large, and the healing required time is long.Therefore, be badly in need of a kind of economical and practical, toxic and side effects is low, and can rapid healing the medicine of above-mentioned disease.
Concha Arcae is the shell of the animal Scapharca subcrenata Arca subcrenata Lischke of Carnis Arca inflata section, Tegillarca granosa Arca granosaLinnaeus or Scapharca broughtonii Arca inflate Reeve, salty in the mouth, and property is flat, returns liver, lung, stomach warp, expectorant blood stasis dispelling, hard masses softening and resolving, relieving gastric hyperacidity to alleviate stomachache.Endoconcha Sepiae is the dry inner shell of Sepiidae animal sepiella maindroni de Rochebrune Sepiellamaindroni de Rochebrune or golden cuttlefish Sepia esculenta Hoyle, and salty in the mouth, puckery is warm in nature, returns spleen, kidney channel, astringing to arrest bleeding, relieving leukorrhea by astringents, antacid, sore can be used for the acid regurgitation of having a stomachache, Peptic Ulcers etc.Report that with Concha Arcae 75% and Radix Glycyrrhizae 25%, red in pulv, treatment gastric and duodenal ulcers, cure rate reaches 76% (" Chinese medicine voluminous dictionary " second edition, Shanghai science tech publishing house, in March, 2006, the 548th～549 page); Human Os Sepiae (life) 250g, Concha Arcae (calcined) 250g are also arranged, Radix Et Rhizoma Rhei 200g, Radix Glycyrrhizae Preparata 200g grinds to the powder, and boiled water is taken after mixing it with water after meal, each 15g, every day 3～4 times, be used for the treatment of peptic ulcer (Gu Linjiang, Cuttlefish Bone Powder for Peptic Ulcer, journal of shanghai Chinese medicine, 9 phases of calendar year 2001); Among the people also multiplex Concha Arcae (vinegar is forged 7 times) 270g, Os Sepiae 180g, Pericarpium citri reticuatae chachiensis (stir-fry) 90g grinds to the powder, every day 3 times, each 6g, boiled water send down the acid regurgitation water that treats for stomachache, eructation, very then haematemesis person after the food.
At present, yet there are no the report of only using vinegar Concha Arcae and Endoconcha Sepiae compound treatment peptic ulcer, chronic erosive gastritis and duodenal erosion.
Summary of the invention
Technical program of the present invention lies in providing the medicine of a kind of effective treatment chronic erosive gastritis, gastric ulcer, duodenal erosion and duodenal ulcer, particularly, the invention provides a kind of pharmaceutical composition for the treatment of digestive tract ulcer, it is the preparation that the crude drug by following weight proportion is prepared from:
4～6 parts of vinegar Concha Arcaes, 1 part of Endoconcha Sepiae.
Further, it is the preparation that the crude drug by following weight proportion is prepared from:
5～6 parts of vinegar Concha Arcaes, 1 part of Endoconcha Sepiae.
Further preferably, it is the preparation that the crude drug by following weight proportion is prepared from:
5.5 parts of vinegar Concha Arcaes, 1 part of Endoconcha Sepiae.
Wherein, described preparation is to be active component by the water of the crude drug of raw material medicated vinegar Concha Arcae and Endoconcha Sepiae or crude drug or extractive with organic solvent, adds what pharmaceutically available adjuvant or complementary composition were prepared from.
Wherein, described preparation is oral formulations.
Further, described oral formulations is powder, granule, pill, capsule, tablet or drop pill.
The present invention also provides a kind of method for preparing above-mentioned pharmaceutical composition, and concrete operation step is as follows:
(1) gets 4～6 parts of vinegar Concha Arcaes, 1 part of Endoconcha Sepiae;
(2) vinegar Concha Arcae, Endoconcha Sepiae are pulverized, sieve, add that pharmaceutically available adjuvant or complementary composition are prepared into preparation.
The present invention also provides the above-mentioned purposes of pharmaceutical composition in the medicine of preparation treatment chronic erosive gastritis.
The present invention also provides the above-mentioned purposes of pharmaceutical composition in the medicine of preparation treatment gastric ulcer.
The present invention also provides the above-mentioned purposes of pharmaceutical composition in the medicine of preparation treatment duodenal erosion.
The present invention also provides the above-mentioned purposes of pharmaceutical composition in the medicine of preparation treatment duodenal ulcer.
Used vinegar Concha Arcae in the pharmaceutical composition of the present invention is to get clean Concha Arcae to put in the appropriate vessel, forges in smokeless stove fire to crisp, takes out and pours in the vinegar, makes quench in vinegar even, dries, and is ground into fine powder.The used vinegar Concha Arcae of writing out a prescription can by existing concocting method self-control, also can be bought the commercial goods and obtain.
Pharmaceutical composition of the present invention has no side effect, can effectively treat Stomach duodenum ulcer, duodenal erosion and chronic erosive gastritis, through clinical verification, this pharmaceutical composition can the rapid recovery Upper abdominal pain etc. clinical symptoms, healing time is short, cure rate provides the new selection of clinical application up to 100% for treatment peptic ulcer, duodenal erosion and chronic erosive gastritis.
Below by the specific embodiment, foregoing of the present invention is described in further detail again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
The specific embodiment
The preparation of embodiment 1 pharmaceutical composition of the present invention
Get vinegar Concha Arcae 5.5g, Endoconcha Sepiae 1g after the pulverizing, crosses 100 mesh sieves, and is encapsulated behind the mix homogeneously, namely gets capsule of the present invention, about every loading amount 0.7g.
The preparation of embodiment 2 pharmaceutical compositions of the present invention
Get vinegar Concha Arcae 5g, Endoconcha Sepiae 1g after the pulverizing, crosses 120 mesh sieves, and is encapsulated behind the mix homogeneously, namely gets capsule of the present invention, about every loading amount 0.7g.
The preparation of embodiment 3 pharmaceutical compositions of the present invention
Get vinegar Concha Arcae 6g, Endoconcha Sepiae 1g after the pulverizing, crosses 100 mesh sieves, and is encapsulated behind the mix homogeneously, namely gets capsule of the present invention, about every loading amount 0.7g.
The preparation of embodiment 4 pharmaceutical compositions of the present invention
Get vinegar Concha Arcae 40g, Endoconcha Sepiae 10g after the pulverizing, crosses 120 mesh sieves, behind the mix homogeneously, namely gets powder of the present invention.
The preparation of embodiment 5 pharmaceutical compositions of the present invention
Get vinegar Concha Arcae 60g, Endoconcha Sepiae 10g after the pulverizing, crosses 80～100 mesh sieves, behind the mix homogeneously, adds an amount of dextrin, steviosin after, granulation namely gets granule of the present invention.
The preparation of embodiment 6 pharmaceutical compositions of the present invention
Get the granule that embodiment 3 prepares, add an amount of magnesium stearate, behind the tabletting, prepare tablet of the present invention.
The preparation of embodiment 7 pharmaceutical compositions of the present invention
Get vinegar Concha Arcae 50g, Endoconcha Sepiae 10g after the pulverizing, crosses 200 mesh sieves, take appropriate amount of PEG 6000 as substrate, be heated to molten condition and Uniform Dispersion after, drop in the liquid paraffin preparation cost invention drop pill.
The preparation of embodiment 8 pharmaceutical compositions of the present invention
Get vinegar Concha Arcae 60g, Endoconcha Sepiae 10g after the pulverizing, crosses 80～100 mesh sieves, behind the mix homogeneously, adds suitable quantity of water or refined honey, by general system or mould method for making, preparation cost invention pill.
The screening of embodiment 9 pharmaceutical composition prescription proportionings of the present invention
By investigating pharmaceutical composition of the present invention to the therapeutical effect of patients w ith peptic ulcer disease, utilize the consumption proportion relation of single blind method screening prescription.In the screening process, selected patient all confirms to suffer from gastric ulcer through scope, selects the administration of following proportioning prescription, and the record patient feedback opinion, the results are shown in Table 1.
Gastric Ulcer standard: upper abdomen dull pain, Tun pain or burn the sample pain, alleviate after taking alkalescent medicine, such pain has rhythmicity, how in 1 hour after the meal, to occur, after 1～2 hour, alleviate gradually, acid regurgitation, belch, heartburn, Abdeminal pain generally also can occur, feel sick, the indigestion symptom such as vomiting; The visible niche of upper digestive tract radiography; Endoscopy, can in stomach see circle or oval, the bottom is smooth, the ulcer of neat in edge, ulcer surface is greyish white or brown tongue film covers edge swelling, color and luster ruddy, smooth and soft (being the gastric ulcer active stage).
Criterion of cure: epigastrium pain disappears, endoscopy, and visible ulcer surface white fur disappears, becomes red congested cicatrix, and visible pleat is concentrated (being cicatricial phase).
Effective standard: epigastrium pain disappears or alleviates, endoscopy, and the attenuation of tongue film, ulcer is dwindled, the blush that visible mucous epithelium is regenerated around it; Or ulcer surface almost disappears, and few thin coating (being healing stage) is arranged on it.
Table 1 prescription the selection result
As shown in Table 1:
(1) although Concha Arcae (calcined) and vinegar Concha Arcae belong to the processed product of Concha Arcae, the drug effect behind the use Concha Arcae (calcined) compatibility is not as good as the vinegar Concha Arcae;
When (2) using separately Concha Arcae, Endoconcha Sepiae, not good to the therapeutic effect of gastric ulcer;
(3) when the vinegar Concha Arcae: when Endoconcha Sepiae was 4: 1, compositions without obviously gastric irritation effect, can be brought into play preferably drug effect; At the vinegar Concha Arcae: Endoconcha Sepiae is 5～6: 1 o'clock, and the therapeutic effect of compositions is best, and its pain relieving antacid successful, and clinical symptoms that can the rapid recovery gastric ulcer are effectively treated gastric ulcer.If vinegar Concha Arcae proportioning consumption is high again, namely close to using separately the vinegar Concha Arcae, its therapeutic effect also is similar to independent use vinegar Concha Arcae, and drug effect is not good.
The above results shows: pharmaceutical composition of the present invention is selected specific Concha Arcae processed product (vinegar Concha Arcae) and specific prescription proportioning (vinegar Concha Arcae: Endoconcha Sepiae=4～6: 1) combine, not only reduced the stimulation of Endoconcha Sepiae to stomach, can also the fast treating gastric ulcer, and pain relieving antacid is respond well, especially when the vinegar Concha Arcae: Endoconcha Sepiae=5～6: in the time of 1, drug side effect obviously reduces, and drug effect significantly is better than other prescriptions, and therapeutic effect is best.
Below further prove beneficial effect of the present invention by clinical practice.
Test example 1 medicine of the present invention is to the treatment of gastric ulcer
Gastric Ulcer standard: see embodiment 9.Accept altogether 1200 examples for medical treatment, endoscopy is confirmed as gastric ulcer.
Therapeutic Method: get the capsule that embodiment 1-3 prepares, use separately, treat respectively the patient of total case number about 1/3, the patient takes 3 every day, each 4, half an hour ante cibum warm water delivery service, period in a medicine is avoided eating anything raw or cold, maror.
Criterion of cure: see embodiment 9.Take medicine continuously by Therapeutic Method, treated 10～15 days, cure 1200 examples, account for 100% of total case.
Test example 2 pharmaceutical compositions of the present invention are to the treatment of duodenal ulcer
Duodenal ulcer diagnostic criteria: epigastrium dull pain, causalgia, distending pain or severe pain, also can be only dull pain discomfort when hunger, or rest pain under slight or the moderate xiphoid-process appears, can be alleviated by antacid or feed, early began to occur upper abdominal pain in 1～3 hour after the meal, just alleviate then will continue to lunch as not taking medicine or taking food after, food also must have meal to alleviate in rear 2～4 hours again bitterly.Endoscopy, thick fur and filth can have petechia, sludged blood on it, the obvious congestion and edema of mucosa is rotten to the corn on every side; Or tongue is still thicker, and the mucosal inflammation edema alleviates on every side, and red re-epithelialize (active stage) can appear in ulcer edge.Accept altogether 200 examples for medical treatment, endoscopy is confirmed as duodenal ulcer.
Therapeutic Method: with test example 1.
Criterion of cure: pain disappears, endoscopy, and white fur disappears, and replaces red epithelium and cicatrix; Or the re-epithelialize redness disappears cicatrix color white (being cicatricial phase).Take medicine continuously by Therapeutic Method, treated 7～10 days, cure 200 examples, account for 100% of total case.
Test example 3 pharmaceutical compositions of the present invention are to the treatment of chronic erosive gastritis
Chronic erosive gastritis diagnostic criteria: the indigestion symptoms such as glutted, acid regurgitation, belch, irregularities stomachache occur, massive bleeding from upper digestive tract can occur, hematemesis, melena occur, shock, normal easily recurrence after the stopped bleeding; Endoscopy, visible gastric mucosa congestion and edema, the some lamellar is rotten to the corn, and the multiple ulcer that differs in size, ulcer surface can have the fresh clot that goes out.Accept altogether 150 examples for medical treatment, endoscopy is confirmed as chronic erosive gastritis.
Therapeutic Method: with test example 1.
Criterion of cure: the indigestion symptoms such as acid regurgitation, stomachache disappear, endoscopy, and rotten to the corn without point-like or lamellar, mucosa edema disappears, and gastric mucosa heals.Take medicine continuously by Therapeutic Method, treated 20～30 days, cure 150 examples, account for 100% of total case.
Test example 4 pharmaceutical compositions of the present invention are to the treatment of duodenal erosion
The duodenal erosion diagnostic criteria: endoscopy, the Duodenal Mucosa layer has red pitting, and the depth is different, shallow person and neck of gland section, dark person reaches muscularis mucosae, but does not pass this layer.Accept altogether 160 examples for medical treatment, endoscopy is confirmed as duodenal erosion.
Therapeutic Method: with test example 1.
Criterion of cure: endoscopy, the Duodenal Mucosa healing without pitting, and does not have cicatrix to leave over.Treated 10～15 days, and cured 160 examples, account for 100% of total case.
In sum, pharmaceutical composition of the present invention has no side effect, can effectively treat Stomach duodenum ulcer, duodenal erosion and chronic erosive gastritis, through clinical verification, this pharmaceutical composition can the rapid recovery Upper abdominal pain etc. clinical symptoms, healing time is short, and cure rate provides the new selection of clinical application up to 100% for treatment peptic ulcer, duodenal erosion and chronic erosive gastritis.
Claims (11)
1. pharmaceutical composition for the treatment of peptic ulcer is characterized in that: it is the preparation that the crude drug by following weight proportion is prepared from:
5～6 parts of vinegar Concha Arcaes; 1 part of Endoconcha Sepiae.
2. pharmaceutical composition according to claim 1 is characterized in that: it is the preparation that the crude drug by following weight proportion is prepared from:
5.5 parts of vinegar Concha Arcaes; 1 part of Endoconcha Sepiae.
3. pharmaceutical composition according to claim 1 and 2, it is characterized in that: described preparation is to be active component by the water of the crude drug of raw material medicated vinegar Concha Arcae and Endoconcha Sepiae or crude drug or extractive with organic solvent, adds what pharmaceutically available adjuvant or complementary composition were prepared from.
4. the described pharmaceutical composition of any one according to claim 1～3, it is characterized in that: described preparation is oral formulations.
5. pharmaceutical composition according to claim 4, it is characterized in that: described oral formulations is powder, granule, pill, capsule or tablet.
6. pharmaceutical composition according to claim 4, it is characterized in that: described oral formulations is drop pill.
7. prepare the method for the described pharmaceutical composition of claim 1～6 any one, it is characterized in that: concrete operation step is as follows:
(1) gets 5～6 parts of vinegar Concha Arcaes, 1 part of Endoconcha Sepiae;
(2) vinegar Concha Arcae, Endoconcha Sepiae are pulverized, sieve, add that pharmaceutically available adjuvant or complementary composition are prepared into preparation.
8. the purposes of the described pharmaceutical composition of claim 1～6 any one in the medicine of preparation treatment chronic erosive gastritis.
9. the purposes of the described pharmaceutical composition of claim 1～6 any one in the medicine of preparation treatment gastric ulcer.
10. the purposes of the described pharmaceutical composition of claim 1～6 any one in the medicine of preparation treatment duodenal erosion.
11. the purposes of the described pharmaceutical composition of claim 1～6 any one in the medicine of preparation treatment duodenal ulcer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100611336A CN102145014B (en) | 2011-03-15 | 2011-03-15 | Pharmaceutical composition for treating peptic ulcer, preparation method and use of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100611336A CN102145014B (en) | 2011-03-15 | 2011-03-15 | Pharmaceutical composition for treating peptic ulcer, preparation method and use of pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102145014A CN102145014A (en) | 2011-08-10 |
| CN102145014B true CN102145014B (en) | 2013-03-13 |
Family
ID=44419616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100611336A Expired - Fee Related CN102145014B (en) | 2011-03-15 | 2011-03-15 | Pharmaceutical composition for treating peptic ulcer, preparation method and use of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102145014B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2532492C1 (en) * | 2013-01-28 | 2014-11-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Method for endoscopic treatment of gastroduodenal ulcers |
| CN103989955A (en) * | 2014-06-16 | 2014-08-20 | 成刚桥 | Pharmaceutical composition for treating stomach and duodenum ulcer, superficial multiple gastric ulcer and erosive gastric ulcer |
| CN110624072A (en) * | 2019-07-29 | 2019-12-31 | 洪光富 | A Chinese medicinal composition for treating duodenal ulcer, gastric erosion, gastric perforation, and superficial gastritis, and its preparation method |
-
2011
- 2011-03-15 CN CN2011100611336A patent/CN102145014B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 于淑芬等.康宁溃疡灵治疗消化性溃疡38例.《陕西中医》.1995,第16卷(第07期),299. * |
| 孙琼等.愈胃散治疗胃十二指肠球部溃疡36例.《青岛医药卫生》.1999,第31卷(第05期),375. * |
| 岳桂华，张栋主编.瓦楞子、海螵蛸.《名医效验药对.内科卷》.2008,第149页. * |
| 张效禹等.甘楞散抗大白鼠胃溃疡作用的实验研究.《辽宁中医杂志》.1980,(第03期),33-35. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102145014A (en) | 2011-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145014B (en) | Pharmaceutical composition for treating peptic ulcer, preparation method and use of pharmaceutical composition | |
| CN106039011A (en) | Traditional Chinese medicine for treating esophagus cancer and preparation method and application thereof | |
| CN105214032A (en) | The solid dispersion tablet for the treatment of peptic ulcer | |
| CN1220517C (en) | Medication for curing disease of stomach intestine | |
| CN105214037A (en) | The solid dispersal capsule for the treatment of peptic ulcer | |
| CN101954060A (en) | Medicament for treating stomach disease | |
| CN100471519C (en) | Medicinal composition for treating gastropathy and its preparing method and use | |
| CN102755419A (en) | Chinese and Western medicine compound preparation for treating chronic gastritis and peptic ulcer | |
| CN1207012C (en) | Medicine for treating digestive system disease and tumor and preparation method thereof | |
| CN1217688C (en) | Medicine for treating chronic gastritis and preparing process thereof | |
| CN1143514A (en) | Medicament and medicinal liquor for treating gastropathy and preparation | |
| CN109394991B (en) | Traditional Chinese medicine compound preparation for treating spleen deficiency and liver depression qi stagnation type chronic atrophic gastritis | |
| CN101019938B (en) | Chinese medicine for treating enteritis and colitis and its preparation method | |
| CN105267929A (en) | Micro-powder capsule for treating peptic ulcer | |
| CN101773607A (en) | Gastric ulcer medicament capsule for treating peptic ulcer with deficiency-cold symptoms | |
| CN104825815A (en) | Traditional Chinese medicine powder for treating peptic ulcer with bleeding and preparation method thereof | |
| CN114984179A (en) | Composition for treating or preventing mitiglinide adverse reaction and preparation method and application thereof | |
| CN105233236A (en) | Powder for treatment of peptic ulcer | |
| CN105267933A (en) | Application of medicine compositions to preparing medicines for treating erosive gastritis | |
| CN1465357A (en) | Chinese patent drug for treating chronic gastritis and chronic gastric ulcer | |
| CN105233239A (en) | Application of medicine composition to preparation of medicine for treating gastric ulcer | |
| CN105233237A (en) | Solid dispersion capsule for treatment of peptic ulcer | |
| CN105267931A (en) | Granules for treating peptic ulcer and method for preparing granules | |
| CN105267928A (en) | Pharmaceutical composition for treating peptic ulcer | |
| CN105267828A (en) | Solid dispersion for treating peptic ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191113 Address after: 620460 No.80, North Road, Qingshen County, Sichuan Province Patentee after: Liu Dong Address before: 620460 North Street Meishan city in Sichuan Province town green Qingshen County No. 71 Patentee before: Liu Zhongming |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |